Guidebook for Diagnosis and Treatment of Hreditary Breast and Ovarian Cancer Syndrome 2017

検索式一覧

Ⅱ-1.遺伝子診断・遺伝カウンセリング領域 / Ⅱ—2.乳癌領域 / Ⅱ—3.婦人科癌領域 / Ⅱ—4.その他の領域

Ⅱ.各 論

Ⅱ—1.遺伝子診断・遺伝カウンセリング領域

■ CQ1 どのような患者にBRCA の遺伝学的検査情報を提供すべきか?

#1  BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#2  ((“Risk Assessment”[TW])OR(evaluation[TIAB])))AND(guideline[TW]))
#3  “Genetic Services”[MH]
#4  (“Risk Assessment”[TW])OR(evaluation[TIAB])
#5  #1 AND #2 AND #3
#6  #1 AND #3 AND #4
#7  #5 OR #6
#8  #7 AND(1994/01[DP]:2016/03[DP])AND English[LA]
■ 検索結果 150 件

■ CQ2 BRCA 遺伝学的検査前の遺伝カウンセリングで提供すべき情報は?

#1  BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#2  neoplasms[MH]OR cancer[TI]
#3  “ Guideline[”PT]OR“Guidelines as Topic”[MH]OR recommendation*[TI]OR statement*[TI]OR guideline*[TI]
#4  genetic service[MH]
#5  #1 OR #2
#6  #1 AND #4 AND #5
#7  #6 AND English[LA]AND 1994/01[DP]:2016/03[DP]
■ 検索結果 358 件

■ CQ3 BRCA 遺伝学的検査前後の遺伝カウンセリングで必要な心理社会的支援は?

※検索式はCQ2 に同じ

■ CQ4  BRCA 以外の遺伝子もマルチ遺伝子パネル検査などを用いて検査を行うことは推奨されるか?

#1  BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#2  FANCJ[TW]OR FANCN[TW]OR RAD51*[TW]OR RAD50[TW]OR ATM[TW]OR NBS1[TW]OR LKB1[TW]OR CDH1[TW]OR CHEK2[TW]OR PTEN[TW]OR STK11[TW]
#3  “ Fanconi Anemia”[TW]OR“Ataxia Telangiectasia”[TW]OR“Nijmegen Breakage Syndrome”[TW]OR“Hamartoma Syndrome, Multiple”[MH]OR“cowden syndrome”[TIAB]OR“Bloom Syndrome”[TW]OR“Peutz—Jeghers Syndrome”[TW]OR“Werner Syndrome”[TW]OR“Xeroderma Pigmentosum”[TW]OR“Li—Fraumeni Syndrome”[TW]
#4  #2 OR #3
#5  #1 AND #4
#6  #5 AND(1994/01[DP]:2016/03[DP])AND English[LA]
■ 検索結果 295 件

■ CQ5 BRCA などの生殖細胞系列変異により,乳癌あるいは卵巣癌のリスクは高まるか?

#1  BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#2  “Germ—Line Mutation”[MAJR]
#3  #1 AND #2
#4  #3 AND Humans[MH]AND 1994/01[DP]:2016/03[DP]AND(English[LA]OR Japanese[LA])
#5 #4 AND“Support of Research”[PT]
■ 検索結果 710 件

■ CQ6  BRCA 遺伝学的検査によって,変異陰性もしくはVUS の結果が得られた場合はどのように対応すべきか?

#1  BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#2  ( ((variant*[TIAB]AND significan*[TIAB])OR VUS[TIAB])OR(mutation*[TW]AND negative[TIAB]))
#3  “Genetic Services”[MH]
#4  #1 AND #2 AND #3
#5  #4 AND Humans[MH]AND 1994/01[DP]:2016/03[DP]AND(English[LA]OR Japanese[LA])
■ 検索結果 351 件

■ CQ7 遺伝学的検査を希望しないクライエントにはどのように対応すべきか?

#1  BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#2  “Genetic Services”[MAJR]
#3  refus*[TIAB]OR reject*[TIAB]OR choice[TW]OR at—risk[TIAB]OR decline[TIAB]OR barrier*[TIAB]
#4  #1 AND #2 AND #3
#5  #4 AND Humans[MH]AND 1994/01[DP]:2016/03[DP]AND(English[LA]OR Japanese[LA])
■ 検索結果 272 件

■ CQ8 遺伝情報の扱いで注意すべき点は何か?

#1 ( “Genetic Testing/ethics”[MH]OR“Genetic Testing/legislation and jurisprudence[”MH]OR“Genetic Testing/organization and administration”[MH]OR“Genetic Testing/supply and distribution”[MH])
#2  privacy[TW]OR confidentiality[MH]
#3  #1 AND #2
#4  Genetic Testing[MAJR]
#5  #3 AND #4
#6  BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#7  discrimination[TW]
#8  #2 OR #7
#9  #4 AND #8
#10  #6 AND #9
#11  #3 AND #6
#12  #10 OR #11
#13  #12 AND Humans[MH]AND 1994/01[DP]:2016/03[DP]AND(English[LA]OR Japanese[LA])
■ 検索結果 75 件

■ CQ9 遺伝学的検査の結果をどのように血縁者に伝えるべきか?

#1  BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#2  “Genetic Services”[MH]
#3  (family[MH])OR(relative*[TIAB])
#4  (Privacy[MH])OR(Confidentiality[MH])OR(“Stress, Psychological”[MH])
#5  #1 AND #2 AND #3 AND #4
#6  #5 AND Humans[MH]AND 1994/01[DP]:2016/03[DP]AND(English[LA]OR Japanese[LA])
■ 検索結果 119 件

■ CQ10 発症前遺伝学的検査は誰を対象とすべきか?

#1 BRCA*[TW]OR“Hereditary Breast and Ovarian Cancer Syndrome”[TW]OR((heredit*[TIAB]OR inherit*[TIAB]OR genet*[TIAB]OR familial*[TIAB]OR mutation*[TIAB])AND(“breast cancer”[TIAB]OR“Breast Neoplasms”[MH]OR“ovarian cancer”[TIAB]OR“Ovarian Neoplasms”[MH]))
#2  “Genetic Services”[MH]
#3  (Family[MH])OR(relative*[TW])OR(adolescen[t MH]OR Child[MH])
#4  ( presymptomati[c TIAB]OR pre—symptomati[c TIAB]OR presymptomati[c TIAB]OR early—symptomatic[TIAB]OR predictiv*[TIAB])
#5  #1 AND #2 AND #3 AND #4
#6  #5 AND Humans[MH]AND 1994/01[DP]:2016/03[DP]AND(English[LA]OR Japanese[LA])
■ 検索結果 72 件

ページTOPへ

Ⅱ—2.乳癌領域

■ CQ11  BRCA 変異を有する乳癌既発症者の対側のリスク低減乳房切除術(CRRM)は推奨されるか?

#1  “Breast Neoplasms/prevention and control”[Mesh]OR“Breast Neoplasms/surgery”[Mesh]
#2  (BRCA*[TW]OR Hereditary Breast and Ovarian Cancer Syndrome[TW])
#3  ( heredit*[tiab]OR inherit*[tiab]OR genet*[tiab]OR familial*[tiab]OR mutat*[tiab])AND(breast cancer[tiab]OR breast neoplasms[MeSH]))
#4  #2 OR #3
#4  mastectomy[tw]
#5  #1 AND #4 AND #5
#6  #5 AND(“1994/01/01”[PDAT]:“2016/03/31”[PDAT])AND((japanese[Language])OR english[Language])
■ 検索結果 682 件

■ CQ12  術前にBRCA 変異保持者であることがわかっている場合,乳房温存療法は推奨されるか?

#1  BRCA*[TW]OR Hereditary Breast and Ovarian Cancer Syndrome[TW]
#2  ( heredit*[tiab]OR inherit*[tiab]OR genet*[tiab]OR familial*[tiab]OR mutat*[tiab])AND(breast cancer[tiab]OR breast neoplasms[MeSH])
#3  #1 OR #2
#4  “Breast neoplasms/therapy”[MeSH]OR breast cancer[tiab]
#5  Mastectomy[MeSH]or mastectom*[tiab]or surgery[tiab]or surgeries[tiab]or breast conserv*[tiab]
#6  #3 AND #4 AND #5 AND(“1994/01/01”[PDAT]:“2016/03/31”[PDAT])AND(japanese[Language]OR english[Language])
■ 検索結果 1,571 件

■ CQ13 BRCA 変異保持者の乳癌化学療法にプラチナ製剤は推奨できるか?

#1  BRCA*[TW]OR Hereditary Breast and Ovarian Cancer Syndrome[TW]
#2  ( heredit*[tiab]OR inherit*[tiab]OR genet*[tiab]OR familial*[tiab]OR mutat*[tiab])AND(breast cancer[tiab]OR breast neoplasms[MeSH])
#3  #1 OR #2
#4  “Breast neoplasms”[MeSH]OR breast cancer[tiab]
#5  “ Organoplatinum Compounds[”Mesh]OR“Platinum Compounds[”Mesh]OR platin*[TW]OR carboplatin[TW]OR cisplatin[TW]OR Nedaplatin[TW]OR oxaliplatin[TW]
#6  #3 AND #4 AND #5 AND(“1994/01/01”[PDAT]:“2016/03/30”[PDAT])AND(japanese[Language]OR english[Language])
■ 検索結果 407 件

■ CQ14  30 歳未満のBRCA 変異保持者にマンモグラフィなどの被曝を伴う画像診断を行うことは推奨されるか?

#1  BRCA*[TW]OR Hereditary Breast and Ovarian Cancer Syndrome[TW]
#2  ( heredit*[tiab]OR inherit*[tiab]OR genet*[tiab]OR familial*[tiab]OR mutat*[tiab])AND(breast cancer[tiab]OR breast neoplasms[MeSH])
#3  #1 OR #2
#4  “ Tomography, X—Ray Computed[”Mesh]or Radiography[Mesh]or Computed Tomograph*[TW]or radiograph*[TW]or X—Ray[TW]or irradiat*[TW]
#5  mass screening[MeSH]OR screen*[TW]OR Early Detection of Cancer[MeSH]OR Sensitivity[TW]OR Specificity[TW]OR detect*[TW]OR“Neoplasms, Radiation—Induced”[Mesh]
#6  #3 AND #4 AND #5 AND(“1994/01/01”[PDAT]:“2016/03/31”[PDAT])AND(japanese[Language]OR english[Language])
■ 検索結果 734 件

■ CQ15  BRCA 変異保持者にMRI は推奨されるか?
もしMRI が実施できない環境ではどのようなサーベイランスが望ましいか?

#1  BRCA*[TW]OR Hereditary Breast and Ovarian Cancer Syndrome[TW]
#2  ( heredit*[tiab]OR inherit*[tiab]OR genet*[tiab]OR familial*[tiab]OR mutat*[tiab])AND(breast cancer[tiab]OR breast neoplasms[MeSH])
#3  #1 OR #2
#4  MRI [TW]OR magnetic resonance imaging[MeSH]OR magnetic resonance imaging[TW]
#5  mass screening[MeSH]OR screen*[TW]OR Early Detection of Cancer[MeSH]OR Sensitivity and Specificity[TW]OR detect*[TW]
#6  #3 AND #4 AND #5
#7  #6 AND(“1994/01/01”[PDAT]:“2016/03/31”[PDAT])AND((japanese[Language])OR english[Language])
■ 検索結果 345 件

■ CQ16—1 リスク低減卵管卵巣切除術(RRSO)は未発症者の乳癌発症の予防に有用か?
    CQ16—2 リスク低減卵管卵巣切除術(RRSO)は既発症者の乳癌発症の予防に有用か?

#1  salpingo—oophorectomy[TW]OR RRSO[TW]OR BSO[TW]OR oophorectomy[TW]OR salpingectomy[TW]OR ovariectomy[TW]OR adnexectomy[TW]OR hysterectomy[TW]
#2  BRCA*[TW]OR Hereditary Breast and Ovarian Cancer Syndrome[TW]
#3  ( heredit*[tiab]OR inherit*[tiab]OR genet*[tiab]OR familial*[tiab]OR mutat*[tiab])AND(breast cancer[tiab]OR breast neoplasms[MeSH])
#4  #2 OR #3
#5  #4 AND(“1994/01/01”[PDAT]:“2016/03/31”[PDAT])AND((japanese[Language])OR english[Language])
■ 検索結果 822 件

■ CQ17  乳癌未発症のBRCA 変異保持者に対し,両側リスク低減乳房切除術(BRRM)は推奨されるか?

#1  “Breast Neoplasms/prevention and control”[Mesh]OR“Breast Neoplasms/surgery”[Mesh]
#2  (BRCA*[TW]OR Hereditary Breast and Ovarian Cancer Syndrome[TW])
#3  ( heredit*[tiab]OR inherit*[tiab]OR genet*[tiab]OR familial*[tiab]OR mutat*[tiab])AND(breast cancer[tiab]OR breast neoplasms[MeSH]))
#4  #2 OR #3
#4  mastectomy[tw]
#5  #1 AND #4 AND #5
#6  #5 AND(“1994/01/01”[PDAT]:“2016/03/31”[PDAT])AND((japanese[Language])OR english[Language])
■ 検索結果 682 件

■ CQ18 乳癌未発症者のBRCA 変異保持者に対し,タモキシフェンによる化学予防は勧められるか?

#1  BRCA*[TW]OR Hereditary Breast and Ovarian Cancer Syndrome[TW]
#2  ( (heredit*[tiab])OR(inherit*[tiab])OR(genet*[tiab])OR(familial*[tiab])OR(mutat*[tiab]))AND((breast cancer[tiab])OR(breast neoplasms[MeSH]))
#3  #1 OR #2
#4  (tamoxifen[TW])OR(tamoxifen[MeSH])OR(Aromatase Inhibitor*[TW])
#5  ( Risk reduction behavio[r MeSH])OR(risk[TW])OR(prevent*[TW])OR(prophylac*[TW])OR(prognosis[MeSH])OR(disease progression[MeSH])
#6  #4 AND #5
#7  #3 AND #6 AND(“1994/01/01”[PDAT]:“2016/03/30”[PDAT])AND((japanese[Language])OR english[Language])
■ 検索結果 593 件

ページTOPへ

Ⅱ—3.婦人科癌領域

■ CQ19 BRCA 変異保持者に対し,リスク低減卵管卵巣摘出術(RRSO)の実施は推奨されるか?

#1  ( (genes, brca[1 MH]OR(gene[s TIAB]AND brca[1 TIAB])OR“brca1 genes”[TIAB]OR brca1[TIAB])))OR((genes, brca2[MH]OR(genes[TIAB]AND brca2[TIAB])OR“brca2 genes”[TIAB]OR brca2[TIAB])
#2  ( ((“risk”[MeSH Terms]OR“risk”[TIAB])AND reducing[TIAB]AND salpingo[TIAB]AND(“ovariectomy”[MeSH Terms]OR“ovariectomy”[TIAB]OR“oophorectomy”[TIAB]))OR RRSO[TIAB])OR(((“risk”[MeSH Terms]OR“risk”[All Fields])AND reducing[All Fields])AND(“surgery”[Subheading]OR“surgery”[All Fields]OR“surgical procedures, operative”[MeSH Terms]))
#3  #1 AND #2
#4  #3 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
#5  #4 AND((“Cochrane Database Syst Rev”[TA]OR“Meta—Analysis”[PT]OR“Practice Guideline”[PT]OR“Guideline”[PT]OR“Guidelines as Topic”[MH]OR Review[PT]OR meta—analysis[TIAB]OR guideline*[TI]OR“systematic review”[TIAB]OR review[TI]OR overview[TI])OR(“Clinical Trials as Topic”[Mesh]OR“Clinical Trial”[PT]OR((clinical trial* OR clinical stud* OR random* OR controlled trial*)NOT medline[SB]))OR(“Research Design”[Mesh]OR“Epidemiologic Study Characteristics as Topic”[Mesh]OR“Study Characteristics”[PT]OR((cohort* OR comparative stud*)NOT medline[SB])))
■ 検索結果 206 件

■ CQ20  BRCA 変異保持者でRRSO が実施されない場合,経腟超音波検査および血清CA125 測定を用いた卵巣癌サーベイランスは勧められるか?

#1  ovarian neoplasms[MeSH Terms]OR(“ovarian”[TIAB]AND“cancer*”[TIAB])OR“ovarian cancer”[TIAB]
#2  ca—125 antigen[MeSH Terms]OR(“ca—125”[TIAB]AND“antigen”[TIAB])OR“ca—125 antigen”[TIAB]OR“ca125”[TIAB]
#3  “ screening”[TIAB]OR“mass screening”[MeSH Terms]OR“screening”[TIAB]OR“early detection of cancer”[MeSH Terms]OR(“early”[TIAB]AND“detection”[TIAB]AND“cancer”[TIAB])OR“early detection of cancer”[TIAB]
#4  #1 AND #2 AND #3
#5  #4 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
#6  #5 AND((“Cochrane Database Syst Rev”[TA]OR“Meta—Analysis”[PT]OR“Practice Guideline”[PT]OR“Guideline”[PT]OR“Guidelines as Topic”[MH]OR Review[PT]OR meta—analysis[TIAB]OR guideline*[TI]OR“systematic review”[TIAB]OR review[TI]OR overview[TI])OR(“Clinical Trials as
Topic”[Mesh]OR“Clinical Trial”[PT]OR((clinical trial* OR clinical stud* OR random* OR controlled trial*)NOT medline[SB]))OR(“Research Design”[Mesh]OR“Epidemiologic Study Characteristics as Topic”[Mesh]OR“Study Characteristics”[PT]OR((cohort* OR comparative stud*)NOT medline
[SB])))
■ 検索結果 403 件

■ CQ21  BRCA 変異保持者の卵巣癌発症リスク低減のために低用量経口避妊薬(OC)あるいは低用量エストロゲン・プロゲスチン配合薬(LEP)投与は推奨されるか?

#1 ( (genes, brca[1 MH]OR(gene[s TIAB]AND brca[1 TIAB])OR“brca1 genes”[TIAB]OR brca1[TIAB])))OR((genes, brca2[MH]OR(genes[TIAB]AND brca2[TIAB])OR“brca2 genes”[TIAB]OR brca2[TIAB])
#2 ( hereditary[TIAB]AND(“breast neoplasms”[MeSH Terms]OR(“breast”[TIAB]AND“neoplasms”[TIAB])OR“breast neoplasms”[TIAB]OR(“breast”[TIAB]AND“cancer”[TIAB])OR“breast cancer”[TIAB])AND(“ovarian neoplasms”[MeSH Terms]OR(“ovarian”[TIAB]AND“neoplasms”[TIAB])
OR“ovarian neoplasms”[TIAB]OR(“ovarian”[TIAB]AND“cancer”[TIAB])OR“ovarian cancer”[TIAB]))OR HBOC[TIAB]OR“breast neoplasms”[MeSH Terms]OR(“breast”[TIAB]AND“neoplasms”[TIAB])OR“breast neoplasms”[TIAB]OR(“breast”[TIAB]AND“cancer”[TIAB])OR“breast cancer”[TIAB]OR ovarian neoplasms
[MeSH Terms]OR(“ovarian”[TIAB]AND“cancer*”[TIAB])OR“ovarian cancer”[TIAB]OR “Fallopian Tube Neoplasms”[Mesh]OR(“fallopian tube”[TIAB]AND cancer*[TIAB])OR(“peritoneum”[MeSH Terms]OR“peritoneum”[TIAB]OR“peritoneal”[TIAB])AND(“neoplasms”[MeSH Terms]OR“cancer*”[TIAB])
#3  “ contraceptives, oral, combined”[Pharmacological Action]OR“contraceptives, oral”[Pharmacological Action]OR“contraceptives, oral, combined”[MeSH Terms OR(“contraceptives”[TIAB]AND“oral”[TIAB]AND“combined”[TIAB])OR“combined oral contraceptives”[TIAB]OR(“birth”[TIAB]
AND“control”[TIAB]AND“pill”[TIAB])OR“birth control pill”[TIAB]OR“contraceptives, oral”[MeSH Terms]OR(“contraceptives”[TIAB]AND“oral”[TIAB])OR“oral contraceptives”[TIAB]OR(“birth”[TIAB]AND“control”[TIAB]AND“pill”[TIAB])
#4  #1 AND #2 AND #3
#5  #4 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
#6  #5 AND((“Cochrane Database Syst Rev”[TA]OR“Meta—Analysis”[PT]OR“Practice Guideline”[PT]OR“Guideline”[PT]OR“Guidelines as Topic”[MH]OR Review[PT]OR meta—analysis[TIAB]OR guideline*[TI]OR“systematic review”[TIAB]OR review[TI]OR overview[TI])OR(“Clinical Trials as
Topic”[Mesh]OR“Clinical Trial”[PT]OR((clinical trial* OR clinical stud* OR random* OR controlled trial*)NOT medline[SB]))OR(“Research Design”[Mesh]OR“Epidemiologic Study Characteristics as Topic”[Mesh]OR“Study Characteristics”[PT]OR((cohort* OR comparative stud*)NOT medline[SB])))
■ 検索結果 89 件

■ CQ22 BRCA 変異保持者に対し,リスク低減卵管摘出術(RRS)は推奨されるか?

#1  ( (genes, brca[1 MH]OR(gene[s TIAB]AND brca[1 TIAB])OR“brca1 genes”[TIAB]OR brca1[TIAB])))OR((genes, brca2[MH]OR(genes[TIAB]AND brca2[TIAB])OR“brca2 genes”[TIAB]OR brca2[TIAB])
#2  ( “risk”[MeSH Terms]OR“risk”[All Fields])AND reducing[All Fields]AND(“salpingectomy”[MeSH Terms]OR“salpingectomy”[All Fields])OR((“risk”[MeSH Terms]OR“risk”[All Fields])AND reducing[All Fields]AND(“surgery”[Subheading]OR“surgery”[All Fields]OR“surgical procedures, operative”
[MeSH Terms]OR(“surgical”[All Fields]AND“procedures”[All Fields]AND“operative”[All Fields])OR“operative surgical procedures”[All Fields]OR“surgery”[All Fields]OR“general surgery”[MeSH Terms]OR(“general”[All Fields]AND“surgery”[All Fields])OR“general surgery”[All Fields]))AND(“fallopian tubes”[MeSH Terms]OR(“fallopian”[All Fields]AND“tubes”[All Fields])OR“fallopian tubes”[All Fields])
#3  ( hereditary[TIAB]AND(“breast neoplasms”[MeSH Terms]OR(“breast”[TIAB]AND“neoplasms”[TIAB])OR“breast neoplasms”[TIAB]OR(“breast”[TIAB]AND“cancer”[TIAB])OR“breast cancer”[TIAB])AND(“ovarian neoplasms”[MeSH Terms]OR(“ovarian”[TIAB]AND“neoplasms”[TIAB])
OR“ovarian neoplasms”[TIAB]OR(“ovarian”[TIAB]AND“cancer”[TIAB])OR“ovarian cancer”[TIAB]))OR HBOC[TIAB]OR ovarian neoplasms[MeSH Terms]OR(“ovarian”[TIAB]AND“cancer*”[TIAB])OR“ovarian cancer”[TIAB]OR“Fallopian Tube Neoplasms”[Mesh]OR(“fallopian tube”[TIAB]AND cancer*[TIAB])OR(“peritoneum”[MeSH Terms]OR“peritoneum”[TIAB]OR“peritoneal”[TIAB])AND(“neoplasms”[MeSH Terms]OR“cancer*”[TIAB])
#4  #1 AND #2 AND #3
#5  #4 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
#6  #5 AND((“Cochrane Database Syst Rev”[TA]OR“Meta—Analysis”[PT]OR“Practice Guideline”[PT]OR“Guideline”[PT]OR“Guidelines as Topic”[MH]OR Review[PT]OR meta—analysis[TIAB]OR guideline*[TI]OR“systematic review”[TIAB]OR review[TI]OR overview[TI])OR(“Clinical Trials as Topic”[Mesh]OR“Clinical Trial”[PT]OR((clinical trial* OR clinical stud* OR random* OR controlled trial*)NOT medline[SB]))OR(“Research Design”[Mesh]OR“Epidemiologic Study Characteristics as Topic”[Mesh]OR“Study Characteristics”[PT]OR((cohort* OR comparative stud*)NOT medline[SB])))
■ 検索結果 52 件

■ CQ23 どのような卵巣癌患者に対してBRCA 遺伝学的検査を行うべきか?

#1  “ BRCA mutations[”TIAB]OR“BRCA1 mutations[”TIAB]OR“BRCA2 mutations[”TIAB]OR“BRCA1/2mutations”[TIAB]OR“BRCA mutation”[TIAB]OR“BRCA1 mutation”[TIAB]OR“BRCA2 mutation”[TIAB]OR“BRCA1/2 mutation”[TIAB]
#2  ( (ovarian neoplasm[s MeSH Terms]OR(“ovarian”[TIAB]AND“cancer*”[TIAB])OR“ovarian cancer”[TIAB]))OR(“tubal cancer”[TIAB]OR(tuba[l TIAB]AND cance[r TIAB])OR“Fallopian Tube Neoplasms”[Mesh]OR(“fallopian tube”[TIAB]AND cancer*[TIAB])))OR((“peritoneum”[MeSH Terms]OR“peritoneum”[TIAB]OR“peritoneal”[TIAB])AND(“neoplasms”[MeSH Terms]OR“cancer*”[TIAB])
#3  testing[TIAB]OR“diagnosis”[Subheading]OR “diagnosis”[TIAB]OR“screening”[TIAB]OR“mass screening”[MeSH Terms]OR(“mass”[TIAB]AND“screening”[TIAB])OR“mass screening”[TIAB]OR “screening”[TIAB]OR “earlydetection of cancer”[MeSH Terms]OR(“early”[TIAB]AND“detection”[TIAB]AND“cancer”[TIAB])OR“early detection of cancer”[TIAB]
#4  “poly(adp—ribose)polymerase inhibitors”[Pharmacological Action]OR“poly(adp—ribose)polymerase inhibitors”[MeSH Terms]OR(“poly(adp—ribose)”[TIAB]AND“polymerase”[TIAB]AND“inhibitors”[TIAB])OR“poly(adp—ribose)polymerase inhibitors”[TIAB]OR(“parp”[TIAB]AND“inhibitor”[TIAB])OR“parp inhibitor”[TIAB]
#5  #1 AND #2 AND(#3 OR #4)
#6  #5 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
#7  #6 AND((“Cochrane Database Syst Rev”[TA]OR“Meta—Analysis”[PT]OR“Practice Guideline”[PT]OR“Guideline”[PT]OR“Guidelines as Topic”[MH]OR Review[PT]OR meta—analysis[TIAB]OR guideline*[TI]OR“systematic review”[TIAB]OR review[TI]OR overview[TI])OR(“Clinical Trials as Topic”[Mesh]OR“Clinical Trial”[PT]OR((clinical trial* OR clinical stud* OR random* OR controlled trial*)NOT medline[SB]))OR(“Research Design”[Mesh]OR“Epidemiologic Study Characteristics as Topic”[Mesh]OR“Study Characteristics”[PT]OR((cohort* OR comparative stud*)NOT medline[SB])))
■ 検索結果 746 件

■ CQ24  卵巣癌例に対するPARP 阻害薬の治療選択を行う際にコンパニオン診断としてBRCA 遺伝学的検査を実施する場合の注意事項は?

※二次資料のみのため検索式なし

■ CQ25 BRCA 変異を有する女性に対して,ホルモン補充療法(HRT)は推奨されるか?

#1  ((genes, brca1[MH]OR(genes[TIAB]AND brca1[TIAB])OR“brca1 genes”[TIAB]OR brca1[TIAB])))OR((genes, brca2[MH]OR(genes[TIAB]AND brca2[TIAB])OR“brca2 genes”[TIAB]OR brca2[TIAB])
#2  hormone replacement therapy[MeSH Terms]OR(“hormone”[TIAB]AND“replacement”[TIAB]AND“therapy”[TIAB])OR“hormone replacement therapy”[TIAB]OR((“hormones”[Pharmacological Action]OR“hormones”[MeSH Terms]OR“hormones”[TIAB]OR“hormone”[TIAB])AND(“therapy”[Subheading]OR“therapy”[TIAB]OR“therapeutics”[MeSH Terms]OR“therapeutics”[TIAB]))OR((“oestrogen”[TIAB]OR“estrogens”[Pharmacological Action]OR“estrogens”[MeSH Terms]OR“estrogens”[TIAB]OR“estrogen”[TIAB])AND(“therapy”[Subheading]OR“therapy”[TIAB]OR“therapeutics”[MeSH Terms]OR“therapeutics”[TIAB]))OR((“oestrogen”[TIAB]OR“estrogens”
[Pharmacological Action]OR“estrogens”[MeSH Terms]OR“estrogens”[TIAB]OR“estrogen”[TIAB])AND(“progestins”[Pharmacological Action]OR“progestins”[MeSH Terms]OR“progestins”[TIAB]OR“progestogen”[TIAB])AND(“therapy”[Subheading]OR“therapy”[TIAB]OR“therapeutics”[MeSH Terms]OR“therapeutics”[TIAB]))
#3  “ovariectomy”[MeSH Terms]OR“ovariectomy”[TIAB]OR“oophorectomy”[TIAB]
#4  #1 AND(#2 OR #3)
#5  #4 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
■ 検索結果 1,083 件

ページTOPへ

Ⅱ—4.その他の領域

■ CQ26 男性の未発症BRCA 変異保持者に対し,前立腺癌のサーベイランスは推奨されるか?

#1 ((genes, brca1[MH]OR(genes[TIAB]AND brca1[TIAB])OR“brca1 genes”[TIAB]OR brca1
[TIAB])))OR((genes, brca2[MH]OR(genes[TIAB]AND brca2[TIAB])OR“brca2 genes”[TIAB]OR
brca2[TIAB])
#2 “prostatic neoplasms”[MH]OR(“prostatic”[TIAB]AND“neoplasms”[TIAB])OR“prostatic neoplasms”
[TIAB]OR(“prostate”[TIAB]AND“neoplasms”[TIAB])OR“prostate neoplasms”[TIAB]OR(“prostate”
[TIAB]AND“cancer”[TIAB])OR“prostate cancer”[TIAB]OR(“prostatic”[TIAB]AND“canser”
[TIAB])OR“prostatic cancer”[TIAB]
#3 #1 AND #2
#4 #3 AND(manegement [TIAB]OR surveillance[TIAB]OR Screening[TIAB]OR
Examination[TIAB]OR Diagnosis[TIAB]OR Monitoring[TIAB])
#5 #4 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
■ 検索結果 124 件

■ CQ27 男性のBRCA 変異保持者に発生した前立腺癌に積極的な治療は勧められるか?

#1  ( (genes, brca[1 MH]OR(gene[s TIAB]AND brca[1 TIAB])OR“brca1 genes”[TIAB]OR brca1[TIAB])))OR((genes, brca2[MH]OR(genes[TIAB]AND brca2[TIAB])OR“brca2 genes”[TIAB]OR brca2[TIAB])
#2  “ prostatic neoplasms”[MH]OR(“prostatic”[TIAB]AND“neoplasms”[TIAB])OR“prostatic neoplasms”[TIAB]OR(“prostate”[TIAB]AND“neoplasms”[TIAB])OR“prostate neoplasms”[TIAB]OR(“prostate”[TIAB]AND“cancer”[TIAB])OR“prostate cancer”[TIAB]OR(“prostatic”[TIAB]AND“canser”[TIAB])OR“prostatic cancer”[TIAB]
#3  #1 AND #2 AND(outcome*[TIAB]OR outlook*[TIAB]OR prognoses[TIAB]OR prognosis*[TIAB]OR pronostic*[TIAB]OR pathological feature[TIAB]OR pathological features[TIAB]OR pathological characteristic[TIAB]OR pathological characteristics[TIAB]OR clinical feature[TIAB]OR clinical features[TIAB]OR clinical characteristic[TIAB]OR clinical characteristics[TIAB])
#4  #3 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
■ 検索結果 60 件

■ CQ28 BRCA 変異保持者における禁煙,食生活など生活習慣の改善に関するエビデンスはあるか?

#1  ( (genes, brca[1 MH]OR(gene[s TIAB]AND brca[1 TIAB])OR“brca1 genes”[TIAB]OR brca1[TIAB])))OR((genes, brca2[MH]OR(genes[TIAB]AND brca2[TIAB])OR“brca2 genes”[TIAB]OR brca2[TIAB])
#2  ( “genes”[MeSH Terms]OR“genes”[TIAB]OR“gene”[TIAB])AND(“mutation”[MeSH Terms]OR“mutation”[TIAB])OR germ—line mutation[MeSH Terms]OR(“germ—line”[TIAB]AND“mutation”[TIAB])OR“germ—line mutation”[TIAB]OR(“germline”[TIAB]AND“mutation”[TIAB])OR“germline mutation”[TIAB]
#3  “ breast neoplasms”[MeSH Terms]OR(“breast”[TIAB]AND“neoplasms”[TIAB])OR“breast neoplasms”
[TIAB]OR(“breast”[TIAB]AND“cancer”[TIAB])OR“breast cancer”[TIAB]
#4  #1 AND #2 AND #3
#5  “ smoking[”MeSH Terms]OR“smoking[”TIAB]OR smok[e MeSH Terms]OR“smoke[”TIAB]OR alcohol drinking[MeSH Terms]OR(“alcohol”[TIAB]AND“drinking”[TIAB])OR“alcohol drinking”[TIAB]OR drinking[TIAB]
#6  weights and measures[MeSH Terms]OR(“weights”[TIAB]AND“measures”[TIAB])OR“weights and measures”[TIAB]OR“weight”[TIAB]OR“body weight”[MeSH Terms]OR(“body”[TIAB]AND“weight”[T I A B])O R“b o d y w e i g h t”[T I A B]O R“b o d y m a s s i n d e x”[M e S H T e r m s]O R(“b o d y”[T I A B]
AND“mass”[TIAB]AND“index”[TIAB])OR“body mass index”[TIAB]OR(BMI [TIAB]NOT brain[TIAB])
#7  motor activity[MeSH Terms]OR(“motor”[TIAB]AND“activity”[TIAB])OR“motor activity”[TIAB]OR(“physical”[TIAB]AND“activity”[TIAB])OR“physical activity”[TIAB]
#8  parity[MeSH Terms]OR“parity”[TIAB]OR(ful[l TIAB]AND(“term birth”[MeSH Terms]OR(“term”[TIAB]AND“birth”[TIAB])OR“term birth”[TIAB]OR“term”[TIAB])AND(“pregnancy”[MeSH Terms]OR“pregnancy”[TIAB]OR“pregnancies”[TIAB]))OR“age at first birth”[TIAB]OR“breast
feeding”[MeSH Terms]OR(“breast”[TIAB]AND“feeding”[TIAB])OR“breast feeding”[TIAB]OR“breastfeeding”[TIAB]OR contraceptives, ora[l Pharmacological Action]OR“contraceptives, oral”[MeSH Terms]OR(“contraceptives”[TIAB]AND“oral”[TIAB])OR“oral contraceptives”[TIAB]OR
(“oral”[TIAB]AND“contraceptive”[TIAB])OR“oral contraceptive”[TIAB]
#9  epidemiologic studies[MeSH Terms]OR(“epidemiologic”[TIAB]AND“studies”[TIAB])OR“epidemiologic studies”[TIAB]OR(“epidemiological”[TIAB]AND“study”[TIAB])OR“epidemiological study”[TIAB]OR(“epidemiologic”[TIAB]AND“research”[TIAB])OR“epidemiologic research”[TIAB]
#10  #5 OR #6 OR #7 OR #8 OR #9
#11  #4 AND #10
#12  #11 AND(JAPANESE[LA]OR ENGLISH[LA])AND 1994:2016[DP]
#13  #12 AND((“Cochrane Database Syst Rev”[TA]OR“Meta—Analysis”[PT]OR“Practice Guideline”[PT]OR“Guideline”[PT]OR“Guidelines as Topic”[MH]OR Review[PT]OR meta—analysis[TIAB]OR guideline*[TI]OR“systematic review”[TIAB]OR review[TI]OR overview[TI])OR(“Clinical Trials as Topic”[Mesh]OR“Clinical Trial”[PT]OR((clinical trial* OR clinical stud* OR random* OR controlled trial*)NOT medline[SB]))OR(“Research Design”[Mesh]OR“Epidemiologic Study Characteristics as Topic”[Mesh]OR“Study Characteristics”[PT]OR((cohort* OR comparative stud*)NOT medline[SB])))
■ 結果件数 85 件

ページTOPへ

PAGETOP